18F-FDG imaging of malignant pleural mesothelioma: Scientiam impendere vero ...

Nuclear Medicine Communications

Volumn 24, Issue 6, 2003, Pages 609-614

  Gerbaudo, V H ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; CANCER STAGING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; EDITORIAL; HUMAN; MESOTHELIOMA; METASTASIS; PATHOLOGY; PLEURA TUMOR; SCINTISCANNING; TUMOR RECURRENCE;

FLUORODEOXYGLUCOSE F18; GIANT LYMPH NODE HYPERPLASIA; HUMANS; MESOTHELIOMA; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PLEURAL NEOPLASMS; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 1542466645     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/01.mnm.0000075188.60210.96     Document Type: Review

References (29)

1. Antman K, Pass H, Schiff P. Benign and malignant pleural mesothelioma. In: DeVita Jr VT, Hellman S, Rosenberg SA, eds. Cancer: principles and practice of oncology. Sixth edition. Philadelphia, PA: Lippincott, 2002: 1943-1969.
2. Price B. Analysis of current trends in United States mesothelioma incidence. Am J Epidemiol 1997; 145: 211-218.
3. Spirtas R, Beebe GW, Connelly RR, et al. Recent trends in mesothelioma incidence in the United States. Am J Ind Med 1986; 9: 397-407.
4. Sugarbaker DJ, Garcia JP, Richards WG, et al. Extrapleural pneumonectomy in the multimodality therapy of malignant pleural mesothelioma. Results in 120 consecutive patients. Ann Surg 1996; 224: 288-296.
5. Boutin C, Rey F, Gouvernet J, Viallat JR, Astoul P, Ledoray V. Thoracoscopy in pleural malignant mesothelioma: a prospective study of 188 consecutive patients. Part prognosis and staging. Cancer 1993; 72: 394-404.
6. Corson JM. Pathology of diffuse malignant pleural mesothelioma. (Review) Semin Thorac Cardiovasc Surg 1997; 9: 347-355.
7. Rusch VW, Venkatraman E. The importance of surgical staging in the treatment of malignant pleural mesothelioma. J Thorac Cardiovasc Surg 1996; 111: 815-825. (Discussion on pp. 825-826.)
8. Leung AN, Muller NL, Miller RR. CT in differential diagnosis of diffuse pleural disease. Am J Roentgenol 1990; 154: 487-492.
9. Sugarbaker DJ, Norberto JJ, Swanson SJ. Extrapleural pneumonectomy in the setting of multimodality therapy for diffuse malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg 1997; 9: 373-382.
10. Kaiser LR, Bavaria JE. Complications of thoracoscopy. Ann Thorac Surg 1993; 56: 796-798.
11. Benard F, Sterman D, Smith RJ, Kaiser LR, Albelda SM, Alavi A. Metabolic imaging of malignant pleural mesothe-lioma with fluorodeoxyglucose positron emission tomography. Chest 1998; 114: 713-722.
12. Schneider DB, Clary-Macy C, Challa S, et al. Positron emission tomography with F18-fluorodeoxyglucose in the staging and preoperative evaluation of malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2000; 120: 128-133.
13. 18F-FDG dual-head gamma-camera coincidence imaging: comparison with histopathol-ogy. J Nucl Med 2002; 43: 1144-1149.
14. Gerbaudo VH, Britz-Cunningham SH, Di Carli MF, Mauceri C, Sugarbaker DJ, Treves ST. Metabolic significance of the pattern, intensity and kinetics of F18-FDG uptake in malignant pleural mesothelioma. (Abstract) Eur J Nucl Med 2002; 29: 265.
15. 18F-FDG positron emission tomography in the evaluation of malignant pleural diseases-a pilot study. Eur J Cardiothorac Surg 2000; 17: 377383.
16. Benard F, Sterman D, Smith RJ, Kaiser LR, Albelda SM, Alavi A. Prognostic value of FDG PET imaging in malignant pleural mesothelioma. J Nucl Med 1999; 40: 1241-1245.
17. Zhuang H, Pourdehnad M, Lambright ES, et al. Dual time point 18F-FDG PET imaging for differentiating malignant from inflammatory processes. J Nucl Med 2001; 42: 14121417.
18. Adler RH, Sayek I. Treatment of malignant pleural effusion: a method using tube thoracostomy and talc. Ann Thorac Surg 1976; 22: 8.
19. Strauss LG. Fluorine-18 deoxyglucose and false-positive results: a major problem in the diagnostics of oncological patients. Eur J Nucl Med 1996; 23: 1409-1415.
20. Bury T, Paulus P, Dowlati A, Corhay JL, Rigo P, Radermecker MF. Evaluation of pleural diseases with FDG-PET imaging: preliminary report. Thorax 1997; 52: 187-189.
21. Patz Jr EF, Shaffer K, Piwnica-Worms DR, et al. Malignant pleural mesothelioma: value of CT and MR imaging in predicting resectability. Am J Roentgenol 1992; 159: 961-966.
22. Sugarbaker DJ, Flores RM, Jaklitsch MT, et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg 1999; 117: 54-65.
23. Rusch VW. A proposed new international TNM staging system for malignant pleural mesothelioma from the International Mesothelioma Interest Group. Lung Cancer 1996; 14: 1-12.
24. Sugarbaker DJ, Strauss GM, Lynch TJ, et al. Node status has prognostic significance in the multimodality therapy of diffuse, malignant mesothelioma. J Clin Oncol 1993; 11: 1172-1178.
25. Marom EM, Erasmus JJ, Pass HI, Patz Jr EF. The role of imaging in malignant pleural mesothelioma. (Review) Semin Oncol 2002; 29: 26-35.
26. Heelan RT. CT and MR imaging in the evaluation of pleural masses. (Review) Chest Surg Clin N Am 1994; 4: 431-450.
27. Oksuzoglu B, Yalcin S, Erman M, Dagdelen S. Leptome-ningeal infiltration of malignant mesothelioma. Med Oncol 2002; 19: 167-169.
28. Baldini EH, Recht A, Strauss GM, et al. Patterns of failure after trimodality therapy for malignant pleural mesothelioma. Ann Thorac Surg 1997; 63: 334-338.
29. Pass HI, Temeck BK, Kranda K, Steinberg SM, Feuerstein IR. Preoperative tumor volume is associated with outcome in malignant pleural mesothelioma. J Thorac Cardiovasc Surg 1998; 115: 310-318.